Open AccessIn vitro susceptibilities and beta-lactamase production of 53 clinical isolates of Branhamella catarrhalis
Author(s) -
Salvador Álvarez,
M. V. Jones,
S Holtsclaw-Berk,
J Guarderas,
Steven L. Berk
Publication year - 1985
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.27.4.646
Subject(s) - ticarcillin , clavulanic acid , microbiology and biotechnology , cephalosporin , antibiotics , antimicrobial , moraxella (branhamella) catarrhalis , neisseria , beta lactamase , moraxella catarrhalis , biology , bacteria , amoxicillin , haemophilus influenzae , escherichia coli , biochemistry , genetics , gene
We tested 53 clinical isolates of Branhamella catarrhalis recovered from patients with respiratory symptoms to determine the susceptibility of the isolates to 25 antimicrobial agents, including the newer beta-lactam antibiotics. Of the 53 strains, 46 (86.7%) were beta-lactamase producers. All the strains were susceptible to the majority of the new penicillins and cephalosporins. The combinations of amoxacillin-clavulanic acid and ticarcillin-clavulanic acid were also very active against the beta-lactamase-producing strains.